Ziopharm: Interim results of ZIO-101 show clinical benefit for solid tumors, leukemia

By Elaine Rigoli

Tampa, Fla., June 2 - Ziopharm Oncology, Inc. said the publication of an abstract discussing interim results of an ongoing phase 1 solid tumor cancer trial with its lead product candidate, ZIO-101, showed six of 24 patients treated had clinical benefit.

Five have stable disease, including two each with renal cell cancer and colorectal cancer and one with head and neck cancer.

One of these with previously rapidly progressing metastatic renal cell cancer had complete resolution of a brain metastasis and stable disease elsewhere.

A sixth with pancreas cancer had a mixed response with a substantial decrease of a liver metastasis, according to a news release.

Ziopharm also said that preliminary results from a phase 1 hematology study of ZIO-101 showed evidence of antileukemia activity in persons with advanced acute myelogenous leukemia.

An antileukemia effect was seen in four of eight patients who had received extensive prior therapies.

Blood leukemia cells disappeared in two patients and were substantially decreased in a third.

The fourth patient stopped requiring frequent red blood cell transfusions and had a marked improvement in functional ability, the release said.

Ziopharm is a biopharmaceutical company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.